Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors

Cancer Prevention Research

Volumn 3, Issue 9, 2010, Pages 1141-1147

  Karoor, Vijaya ^a,c   Le, Mysan ^b   Merrick, Daniel ^a,b,c   Dempsey, Edward C ^a,b,c   Miller, York E ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY DC101; URETHAN; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOGENS; CHEMOPREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; URETHANE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77956400094     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0005     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9. (Pubitemid 40216240)
3. Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. Cancer 1996;78:1004-10.
4. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
5. Abdollahi A, Schwager C, Kleeff J, et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A 2007;104:12890-5.
6. Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 2009;70:93-102.
7. Keith RL, Miller YE, Gemmill RM, et al. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 2000;6:1616-25.
8. Merrick DT, Haney J, Petrunich S, et al. Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. Lung Cancer 2005;48:31-45.
9. Bhat TA, Singh RP. Tumor angiogenesis - a potential target in cancer chemoprevention. Food Chem Toxicol 2008;46:1334-45.
10. Jiang C, Jiang W, Ip C, Ganther H, Lu J. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999;26:213-25.
11. Noonan DM, Benelli R, Albini A. Angiogenesis and cancer prevention: a vision. Recent Results Cancer Res 2007;174:219-24.
12. Malkinson AM. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res 1992;52:2670-6s.
13. Stearman RS, Dwyer-Nield L, Zerbe L, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005;167:1763-75.
14. Wang Y, Zhang Z, Yan Y, et al. A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility. Cancer Res 2004;64:1647-54. (Pubitemid 38428685)
15. Wang Y, Zhang Z, Garbow JR, et al. Chemoprevention of lung squamous cell carcinoma in mice by a mixture of Chinese herbs. Cancer Prev Res 2009;2:634-40.
16. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008;61:179-88.
17. Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17:155-61.
18. Alferez D, Wilkinson RW, Watkins J, et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. Mol Cancer Ther 2008;7:590-8.
19. Keith RL, Miller YE, Hoshikawa Y, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002;62:734-40. (Pubitemid 34126948)
20. Keith RL, Miller YE, Hudish TM, et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004;64:5897-904.
21. Nemenoff R, Meyer AM, Hudish TM, et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ. Cancer Prev Res 2008;1:349-56.
22. Yan Y, Lu Y, Wang M, et al. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 2006;4:971-81. (Pubitemid 46121555)
23. Fujimoto N, Wislez M, Zhang J, et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005;65:11478-85.
24. Kishino D, Kiura K, Takigawa N, et al. Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanoneinduced lung tumorigenesis in A/J mice. Lung Cancer 2009;64:284-9.
25. Ohashi K, Takigawa N, Osawa M, et al. Chemopreventive effects of gefitinib onnonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res 2009;69:7088-95.
26. Tang X, Varella-Garcia M, Xavier AC, et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008;1:192-200.
27. Ohashi K, Rai K, Fujiwara Y, et al. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Sci 2008;99:1747-53.
28. Byers T, Wolf HJ, Franklin WA, et al. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev 2008;17:158-62.
29. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8.
30. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, et al. Familial risk of lung carcinoma in the Icelandic population. JAMA 2004;292:2977-83.